A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

BackgroundsAs a new oral chemotherapy drug, TAS-102 is currently recommended as the third-line treatment for metastatic colorectal cancer (mCRC). Recently, studies have reported the efficacy of TAS-102 combined with bevacizumab in colon cancer patients after standard treatment fails. Here, we evalua...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaochen Chen, Huafeng Qiu, Yunwang Chen, Mingxing Wang, Pengfei Zhu, Shuangyue Pan, Yaya Deng, Liu Yang, Zheling Chen
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	TAS-102 bevacizumab colorectal cancer meta-analysis 3 survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5a76542d8711429db90335abfcc39a75
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5a76542d8711429db90335abfcc39a75
record_format	dspace
spelling	oai:doaj.org-article:5a76542d8711429db90335abfcc39a752021-11-18T08:57:12ZA Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis2234-943X10.3389/fonc.2021.690515https://doaj.org/article/5a76542d8711429db90335abfcc39a752021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.690515/fullhttps://doaj.org/toc/2234-943XBackgroundsAs a new oral chemotherapy drug, TAS-102 is currently recommended as the third-line treatment for metastatic colorectal cancer (mCRC). Recently, studies have reported the efficacy of TAS-102 combined with bevacizumab in colon cancer patients after standard treatment fails. Here, we evaluated the efficacy and safety of TAS-102 combined with bevacizumab versus TAS-102 as a single agent by a systematic review and a meta-analysis.MethodsPubMed, Web of Science and Cochrane libraries were searched. Studies involving bevacizumab combined with TAS-102 in mCRC were included. Study characteristics (author, year of publication, country et al.), efficacy (disease control rate(DCR), progression-free survival(PFS), overall survival(OS)) and adverse effects were extract from studies. Forest plots were created based on Cox model analysis.ResultsAfter screening 550 studies, a total of 3 studies were included, which compared the safety and effectiveness of TAS-102 with or without bevacizumab. Analysis based on Cox regression showed that the combined treatment group had advantages in 6-month (OR= 2.93, 95% CI: 1.72 to 5.00, P<0.0001), 12-month(OR= 2.18, 95% CI: 1.24 to 3.81, P=0.006), and 18-month (OR=3.08, 95% CI: 1.34 to 7.12, P=0.008) OS. The combined treatment group demonstrated superiority in 6-month PFS rates (OR= 2.50, 95% CI: 1.18 to 5.31, P=0.02). The incidence of thrombocytopenia in the dual-drug treatment group was higher (OR= 1.96, 95% CI: 1.14 to 3.36 P=0.01). The proportion of serious adverse events were similar in tow groups (OR= 1.01, 95% CI: 0.76 to 1.34 P=0.93).ConclusionBevacizumab combined with TAS-102 could improve the prognosis of patients with mCRC who have failed standard treatment. In terms of side effects, the addition of bevacizumab did not increase serious adverse reactions, but the occurrence of thrombocytopenia was worth noting.Xiaochen ChenHuafeng QiuYunwang ChenYunwang ChenMingxing WangMingxing WangPengfei ZhuPengfei ZhuShuangyue PanShuangyue PanYaya DengYaya DengLiu YangZheling ChenFrontiers Media S.A.articleTAS-102bevacizumabcolorectal cancermeta-analysis 3survivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	TAS-102 bevacizumab colorectal cancer meta-analysis 3 survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	TAS-102 bevacizumab colorectal cancer meta-analysis 3 survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Xiaochen Chen Huafeng Qiu Yunwang Chen Yunwang Chen Mingxing Wang Mingxing Wang Pengfei Zhu Pengfei Zhu Shuangyue Pan Shuangyue Pan Yaya Deng Yaya Deng Liu Yang Zheling Chen A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
description	BackgroundsAs a new oral chemotherapy drug, TAS-102 is currently recommended as the third-line treatment for metastatic colorectal cancer (mCRC). Recently, studies have reported the efficacy of TAS-102 combined with bevacizumab in colon cancer patients after standard treatment fails. Here, we evaluated the efficacy and safety of TAS-102 combined with bevacizumab versus TAS-102 as a single agent by a systematic review and a meta-analysis.MethodsPubMed, Web of Science and Cochrane libraries were searched. Studies involving bevacizumab combined with TAS-102 in mCRC were included. Study characteristics (author, year of publication, country et al.), efficacy (disease control rate(DCR), progression-free survival(PFS), overall survival(OS)) and adverse effects were extract from studies. Forest plots were created based on Cox model analysis.ResultsAfter screening 550 studies, a total of 3 studies were included, which compared the safety and effectiveness of TAS-102 with or without bevacizumab. Analysis based on Cox regression showed that the combined treatment group had advantages in 6-month (OR= 2.93, 95% CI: 1.72 to 5.00, P<0.0001), 12-month(OR= 2.18, 95% CI: 1.24 to 3.81, P=0.006), and 18-month (OR=3.08, 95% CI: 1.34 to 7.12, P=0.008) OS. The combined treatment group demonstrated superiority in 6-month PFS rates (OR= 2.50, 95% CI: 1.18 to 5.31, P=0.02). The incidence of thrombocytopenia in the dual-drug treatment group was higher (OR= 1.96, 95% CI: 1.14 to 3.36 P=0.01). The proportion of serious adverse events were similar in tow groups (OR= 1.01, 95% CI: 0.76 to 1.34 P=0.93).ConclusionBevacizumab combined with TAS-102 could improve the prognosis of patients with mCRC who have failed standard treatment. In terms of side effects, the addition of bevacizumab did not increase serious adverse reactions, but the occurrence of thrombocytopenia was worth noting.
format	article
author	Xiaochen Chen Huafeng Qiu Yunwang Chen Yunwang Chen Mingxing Wang Mingxing Wang Pengfei Zhu Pengfei Zhu Shuangyue Pan Shuangyue Pan Yaya Deng Yaya Deng Liu Yang Zheling Chen
author_facet	Xiaochen Chen Huafeng Qiu Yunwang Chen Yunwang Chen Mingxing Wang Mingxing Wang Pengfei Zhu Pengfei Zhu Shuangyue Pan Shuangyue Pan Yaya Deng Yaya Deng Liu Yang Zheling Chen
author_sort	Xiaochen Chen
title	A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
title_short	A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
title_full	A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
title_fullStr	A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
title_full_unstemmed	A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
title_sort	comparison of bevacizumab plus tas-102 and tas-102 monotherapy for metastatic colorectal cancer: a systematic review and meta-analysis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/5a76542d8711429db90335abfcc39a75
work_keys_str_mv	AT xiaochenchen acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT huafengqiu acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT yunwangchen acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT yunwangchen acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT mingxingwang acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT mingxingwang acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT pengfeizhu acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT pengfeizhu acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT shuangyuepan acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT shuangyuepan acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT yayadeng acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT yayadeng acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT liuyang acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT zhelingchen acomparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT xiaochenchen comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT huafengqiu comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT yunwangchen comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT yunwangchen comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT mingxingwang comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT mingxingwang comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT pengfeizhu comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT pengfeizhu comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT shuangyuepan comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT shuangyuepan comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT yayadeng comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT yayadeng comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT liuyang comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis AT zhelingchen comparisonofbevacizumabplustas102andtas102monotherapyformetastaticcolorectalcancerasystematicreviewandmetaanalysis
_version_	1718421082979958784

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

Ejemplares similares